Stoke Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview

Stoke Therapeutics

02/05/2025 15:18

Stoke Therapeutics Inc STOK.OQ STOK.O is expected to show a rise in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

The Bedford Massachusetts-based  company is expected to report a 80.6% increase in revenue to $7.614 million from $4.22 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Stoke Therapeutics Inc is for a loss of 43 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 2.0% in the last three months. ​

Wall Street's median 12-month price target for Stoke Therapeutics Inc is $21.00​, above​ its last closing price of $9.87. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.52
-0.53
-0.18
Beat
65.9
Sep. 30 2024
-0.53
-0.53
-0.47
Beat
11.8
Jun. 30 2024
-0.56
-0.56
-0.46
Beat
17.9​
Mar. 31 2024
-0.61
-0.61
-0.57
Beat
6.6
​​Dec. 31 2023
-0.48
-0.63
-0.60
Beat
4.8
Sep. 30 2023
-0.64
-0.63
-0.55
Beat
12.4​
Jun. 30 2023
-0.62
-0.64
-0.69
Missed
-8.4
Mar. 31 2023
-0.68
-0.70
-0.53
Beat
23.9

This summary was machine generated May 2 at 14:18 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)